Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Pediatric Aerodigestive Medicine: Advancing Collaborative Care for Children With Oropharyngeal Dysphagia
Krasaelap, Amornluck , Sabe, Ramy , Bhardwaj, Vrinda, Lerner, Diana G. , Gold, Benjamin D., Boesch, R. Paul , Allmen, Daniel von, Williams, Dana , Chiou, Eric , DeBoer, Emily M. , Hysinger, Erik B. , Maybee, Jennifer , Khlevner, Julie , Larson, Kara , Morris, Kimberly , Jalali, Lauren , McSweeney, Maireade E. , Greifer, Melanie , Rutter, Michael J. , Williams, Nina, Subramanyan, Ram Kumar, Ryan, Matthew J. , Acra, Sari , Pentiuk, Scott, Friedlander, Joel A. , Sobol, Steven E., Kaul, Ajay , Dorfman, Lev , Darbari, Anil , Prager, Jeremy D. , Rosen, Rachel , Cocjin, Jose, Kumar, S. Ram , Boesch, Richard Paul, Kumar, S Ram , Rosen, Rachel , Duncan, Daniel R. , Faure, Christophe C. , Brigger, Matthew T. , Mousa, Hayat M.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | July 13, 2023 | Volume: 77 | Issue: 4 | Pages: 460-467

10.1097/mpg.0000000000003882 | PMID 37438891 Get It

Objectives:Aerodigestive disorders encompass various pathological conditions affecting the lungs, upper airway, and gastrointestinal tract in children. While advanced care has primarily occurred in specialty centers, many children first present to general pediatric gastroenterologists with aerodigestive symptoms necessitating awareness of these conditions. At the 2021 Annual North American Society for Pediatric Gastroenterology, Hepatology and Nutrition meeting, the aerodigestive Special Interest Group held a full‐day symposium entitled, Pediatric Aerodigestive Medicine: Advancing Collaborative Care of Children with Aerodigestive Disorders. The symposium aimed to underline the significance of a multidisciplinary approach to achieve better outcomes for these complex patients.Methods:The symposium brought together leading experts to highlight the growing aerodigestive field, promote new scientific and therapeutic strategies, share the structure and benefits of a multidisciplinary approach in diagnosing common and rare aerodigestive disorders, and foster multidisciplinary discussion of complex cases while highlighting the range of therapeutic and diagnostic options. In this article, we showcase the diagnostic and therapeutic approach to oropharyngeal dysphagia (OPD), one of the most common aerodigestive conditions, emphasizing the role of a collaborative model.Conclusions:The aerodigestive field has made significant progress and continues to grow due to a unique multidisciplinary, collaborative model of care for these conditions. Despite diagnostic and therapeutic challenges, the multidisciplinary approach has enabled and greatly improved efficient, high‐quality, and evidence‐based care for patients, including those with OPD.
Modest Effects of Osteoclast‐Specific ERα Deletion after Skeletal Maturity
Doolittle, Madison L. , Eckhardt, Brittany, Vos, Stephanie J. B. , Grain, Sarah, Rowsey, Jennifer L. , Ruan, Ming, Saul, Dominik , Farr, Joshua N. , Weivoda, Megan , Khosla, Sundeep , Eckhardt, Brittany A, Vos, Stephanie J, Weivoda, Megan M, Monroe, David G , Khosla, Sundeep , Farr, Joshua N , Saul, Dominik , Vos, Stephanie J., Monroe, David G.

Mayo Clinic

JBMR Plus | July 13, 2023 | Volume: 7 | Issue: 10 | Pages: No page available

10.1002/jbm4.10797 | PMID 37808391 Get It

ABSTRACT Estrogen regulates bone mass in women and men, but the underlying cellular mechanisms of estrogen action on bone remain unclear. Although both estrogen receptor (ER)α and ERβ are expressed in bone cells, ERα is the dominant receptor for skeletal estrogen action. Previous studies using either global or cell‐specific ERα deletion provided important insights, but each of these approaches had limitations. Specifically, either high circulating sex steroid levels in global ERα knockout mice or the effects of deletion of ERα during growth and development in constitutive cell‐specific knockout mice have made it difficult to clearly define the role of ERα in specific cell types in the adult skeleton. We recently generated and characterized mice with tamoxifen‐inducible ERα deletion in osteocytes driven by the 8‐kb Dmp1 promoter (ERαΔOcy mice), revealing detrimental effects of osteocyte‐specific ERα deletion on trabecular bone volume (−20.1%) and bone formation rate (−18.9%) in female, but not male, mice. Here, we developed and characterized analogous mice with inducible ERα deletion in osteoclasts using the Cathepsin K promoter (ERαΔOcl mice). In a study design identical to that with the previously described ERαΔOcy mice, adult female, but not male, ERαΔOcl mice showed a borderline (−10.2%, p = 0.084) reduction in trabecular bone volume, no change in osteoclast numbers, but a significant increase in serum CTx levels, consistent with increased osteoclast activity. These findings in ERαΔOcl mice differ from previous studies of constitutive osteoclast‐specific ERα deletion, which led to clear deficits in trabecular bone and increased osteoclast numbers. Collectively, these data indicate that in adult mice, estrogen action in the osteocyte is likely more important than via the osteoclast and that ERα deletion in osteoclasts from conception onward has more dramatic skeletal effects than inducible osteoclastic ERα deletion in adult mice. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Statistical Considerations and Software for Designing Sequential, Multiple Assignment, Randomized Trials (SMART) with a Survival Final Endpoint
Kravets, Sasha , Ruppert, Amy S. , Mandrekar, Sumithra J. , Jacobson, Sawyer B, Jacobson, Sawyer , Le‐Rademacher, Jennifer

Mayo Clinic

Journal of Biopharmaceutical Statistics | July 12, 2023 | Volume: 34 | Issue: 4 | Pages: 539-552

10.1080/10543406.2023.2233616 | PMID 37434437 Get It

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Litton, Jennifer K. , Regan, Meredith M. , Pusztai, Lajos , Tolaney, Sara M. , Garrett‐Mayer, Elizabeth , Amiri‐Kordestani, Laleh , Basho, Reva , Boileau, Jean-François , Foster, Jared C. , Jacene, Heather A. , King, Tari A. , Mason, Ginny, O’Sullivan, Ciara C. , Prowell, Tatiana M. , Richardson, Andrea L. , Sepulveda, Karla A., Smith, Mary Lou , Tjoe, Judy A., Turashvili, Gulisa , Butler, Lynn Pearson, Schwartz, Elena I., Korde, Larissa A. , Rugo, Hope S , Tolaney, Sara , Garrett-Mayer, Elizabeth , Amiri-Kordestani, Laleh , Basho, Reva K , Best, Ana F , Boileau, Jean-Francois , Denkert, Carsten , Foster, Jared C , Harbeck, Nadia , Jacene, Heather A , O'Sullivan, Ciara Catherine , Prowell, Tatiana M , Turashvili, Gulisa , Woodward, Wendy A , Pusztai, Lajos , Rugo, Hope S.

Mayo Clinic

Journal of Clinical Oncology | July 11, 2023 | Volume: 41 | Issue: 27 | Pages: 4433-4442

10.1200/jco.23.00435 | PMID 37433103 Get It

PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points. METHODS The NeoSTEEP working group concentrated on neoadjuvant systemic therapy end points in clinical trials with efficacy outcomes—both pathologic and time-to-event survival end points—particularly for registrational intent. Special considerations for subtypes and therapeutic approaches, imaging, nodal staging at surgery, bilateral and multifocal diseases, correlative tissue collection, and US Food and Drug Administration regulatory considerations were contemplated. RESULTS The working group recommends a preferred definition of pathologic complete response (pCR) as the absence of residual invasive cancer in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0 per AJCC staging). Residual cancer burden should be a secondary end point to facilitate future assessment of its utility. Alternative end points are needed for hormone receptor–positive disease. Time-to-event survival end point definitions should pay particular attention to the measurement starting point. Trials should include end points originating at random assignment (event-free survival and overall survival) to capture presurgery progression and deaths as events. Secondary end points adapted from STEEP 2.0, which are defined from starting at curative-intent surgery, may also be appropriate. Specification and standardization of biopsy protocols, imaging, and pathologic nodal evaluation are also crucial. CONCLUSION End points in addition to pCR should be selected on the basis of clinical and biologic aspects of the tumor and the therapeutic agent investigated. Consistent prespecified definitions and interventions are paramount for clinically meaningful trial results and cross-trial comparison.
Network Connectivity Alterations across the MAPT Mutation Clinical Spectrum
Zhang, Liwen , Flagan, Taru , Häkkinen, Suvi , Chu, Stephanie A. , Brown, Jesse A. , Lee, Alex J. , Mandelli, Maria Luisa , Gorno‐Tempini, Maria Luisa , Sturm, Virginia E. , Yokoyama, Jennifer S. , Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Kantarci, Kejal , Lago, Argentina Lario , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Ramos, Eliana Marisa , Roberson, Erik D. , Weıntraub, Sandra , Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Lee, Suzee E. , Consortia, the ARTFL/LEFFTDS/ALLFTD, Kantarci, Kejal , Tartaglia, Maria Carmela , Lee, Suzee E , Roberson, Erik , Yokoyama, Jennifer , Domoto-Reilly, Kimiko , Pasquini, Lorenzo , Appleby, Brian S. , Cobigo, Yann , Dickerson, Bradford Clark , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Litvan, Irene , Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , Miller, Bruce L. , Seeley, William W. , Consortia, the ARTFL/LEFFTDS/ALLFTD

Mayo Clinic

Annals of Neurology | July 11, 2023 | Volume: 94 | Issue: 4 | Pages: 632-646

10.1002/ana.26738 | PMID 37431188 Get It

ObjectiveMicrotubule‐associated protein tau (MAPT) mutations cause frontotemporal lobar degeneration, and novel biomarkers are urgently needed for early disease detection. We used task‐free functional magnetic resonance imaging (fMRI) mapping, a promising biomarker, to analyze network connectivity in symptomatic and presymptomatic MAPT mutation carriers.MethodsWe compared cross‐sectional fMRI data between 17 symptomatic and 39 presymptomatic carriers and 81 controls with (1) seed‐based analyses to examine connectivity within networks associated with the 4 most common MAPT‐associated clinical syndromes (ie, salience, corticobasal syndrome, progressive supranuclear palsy syndrome, and default mode networks) and (2) whole‐brain connectivity analyses. We applied K‐means clustering to explore connectivity heterogeneity in presymptomatic carriers at baseline. Neuropsychological measures, plasma neurofilament light chain, and gray matter volume were compared at baseline and longitudinally between the presymptomatic subgroups defined by their baseline whole‐brain connectivity profiles.ResultsSymptomatic and presymptomatic carriers had connectivity disruptions within MAPT‐syndromic networks. Compared to controls, presymptomatic carriers showed regions of connectivity alterations with age. Two presymptomatic subgroups were identified by clustering analysis, exhibiting predominantly either whole‐brain hypoconnectivity or hyperconnectivity at baseline. At baseline, these two presymptomatic subgroups did not differ in neuropsychological measures, although the hypoconnectivity subgroup had greater plasma neurofilament light chain levels than controls. Longitudinally, both subgroups showed visual memory decline (vs controls), yet the subgroup with baseline hypoconnectivity also had worsening verbal memory and neuropsychiatric symptoms, and extensive bilateral mesial temporal gray matter decline.InterpretationNetwork connectivity alterations arise as early as the presymptomatic phase. Future studies will determine whether presymptomatic carriers' baseline connectivity profiles predict symptomatic conversion. ANN NEUROL 2023;94:632–646
Event-Related Potential Markers of Suicidality in Adolescents
Camsari, Deniz Doruk, Lewis, Charles P. , Sonmez, Ayse Irem , Fatih, Parmis , Yuruk, Deniz , Shekunov, Julia , Voort, Jennifer L. Vande , Croarkin, Paul E. , Doruk Camsari, Deniz, Özger, Can , Croarkin, Paul E

Mayo Clinic

International Journal of Neuropsychopharmacology | July 9, 2023 | Volume: 26 | Issue: 8 | Pages: 566-575

10.1093/ijnp/pyad039 | PMID 37422891 Get It

Abstract Background Implicit cognitive markers may assist with the prediction of suicidality beyond clinical risk factors. The aim of this study was to investigate neural correlates associated with the Death/Suicide Implicit Association Test (DS-IAT) via event-related potentials (ERP) in suicidal adolescents. Methods Thirty inpatient adolescents with suicidal ideations and behaviors (SIBS) and 30 healthy controls from the community were recruited. All participants underwent 64-channel electroencephalography, DS-IAT, and clinical assessments. Hierarchical generalized linear models with spatiotemporal clustering were used to identify significant ERPs associated with the behavioral outcome of DS-IAT (D scores) and group differences. Results Behavioral results (D scores) showed that the adolescents with SIBS had stronger implicit associations between “death” and “self” than the healthy group (P = .02). Within adolescents with SIBS, participants with stronger implicit associations between “death” and “self” reported more difficulty in controllability of suicidal ideation in the past 2 weeks based on the Columbia-Suicide Severity Rating Scale (P = .03). For the ERP data, the D scores and N100 component over the left parieto-occipital cortex had significant correlations. Significant group differences without behavioral correlation were observed for a second N100 cluster (P = .01), P200 (P = .02), and late positive potential (5 clusters, all P ≤ .02). Exploratory predictive models combining both neurophysiological and clinical measures distinguished adolescents with SIBS from healthy adolescents. Conclusions Our results suggest that N100 may be a marker of attentional resources involved in the distinction of stimuli that are congruent or incongruent to associations between death and self. Combined clinical and ERP measures may have utility in future refinements of assessment and treatment approaches for adolescents with suicidality.
Hearing, β-Amyloid Deposition and Cognitive Test Performance in Black and White Older Adults: The ARIC-PET Study
Deal, Jennifer A. , Jiang, Kening , Sharrett, A. Richey , Reed, Nicholas S. , Knopman, David S. , Wong, Dean F. , Lin, Frank R. , Knopman, David S. , Deal, Jennifer A , Rawlings, Andreea M. , Mosley, Thomas H. , Zhou, Yun , Gottesman, Rebecca F.

Mayo Clinic

The Journals of Gerontology: Series A | July 7, 2023 | Volume: 78 | Issue: 11 | Pages: 2105-2110

10.1093/gerona/glad159 | PMID 37419460 Get It

Abstract Background Hearing loss is a risk factor for dementia; whether the association is causal or due to a shared pathology is unknown. We estimated the association of brain β-amyloid with hearing, hypothesizing no association. As a positive control, we quantified the association of hearing loss with neurocognitive test performance. Methods Cross-sectional analysis of Atherosclerosis Risk in Communities-Positron Emission Tomography study data. Amyloid was measured using global cortical and temporal lobe standardized uptake value ratios (SUVRs) calculated from florbetapir-positron emission tomography scans. Composite global and domain-specific cognitive scores were created from 10 neurocognitive tests. Hearing was measured using an average of better-ear air conduction thresholds (0.5–4 kHz). Multivariable-adjusted linear regression estimated mean differences in hearing by amyloid and mean differences in cognitive scores by hearing, stratified by race. Results In 252 dementia-free adults (72–92 years, 37% Black race, and 61% female participants), cortical or temporal lobe SUVR was not associated with hearing (models adjusted for age, sex, education, and APOE ε4). Each 10 dB HL increase in hearing loss was associated with a 0.134 standard deviation lower mean global cognitive factor score (95% CI: −0.248, −0.019), after adjustment for demographic and cardiovascular factors. Observed hearing-cognition associations were stronger in Black versus White participants. Conclusions Amyloid is not associated with hearing, suggesting that pathways linking hearing and cognition are independent of this pathognomonic Alzheimer’s-related brain change. This is the first study to show that the impact of hearing loss on cognition may be stronger in Black versus White adults.
American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines
Hallemeier, Christopher L. , Sharma, Navesh , Anker, Christopher J. , Lee, Percy, Williams, Vonetta M. , Kennedy, Timothy J., Jethwa, Krishan R. , Kumar, Rachit , Russo, Suzanne , Jethwa, Krishan , Small, William , Hallemeier, Christopher Leigh , Selfridge, Jennifer Eva , Lee, Percy , Jabbour, Salma K , Liu, David M. , Kim, Ed, Tchelebi, Leila T. , Russo, Suzanne

Mayo Clinic

Cancer | July 6, 2023 | Volume: 129 | Issue: 20 | Pages: 3193-3212

10.1002/cncr.34931 | PMID 37409678 Get It

AbstractThe liver is a common site of cancer metastases. Systemic therapy is widely accepted as the standard treatment for liver metastases (LM), although select patients with liver oligometastases may be candidates for potentially curative liver resection. Recent data support the role of nonsurgical local therapies such as ablation, external beam radiotherapy, embolization, and hepatic artery infusion therapy for management of LM. Additionally, for patients with advanced, symptomatic LM, local therapies may provide palliative benefit. The American Radium Society gastrointestinal expert panel, including members representing radiation oncology, interventional radiology, surgical oncology, and medical oncology, performed a systemic review and developed Appropriate Use Criteria for the use of nonsurgical local therapies for LM. Preferred Reporting Items for Systematic reviews and Meta‐Analyses methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established consensus methodology (modified Delphi). A summary of recommendations is outlined to guide practitioners on the use of nonsurgical local therapies for patients with LM.
Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias
Moser, Ethan D. , Manemann, Sheila M., Larson, Nicholas B. , Mielke, Michelle M. , Rocca, Walter A. , Roger, Véronique L. , Remaley, Alan T. , Decker, Paul A. , Killian, Jill M. , Takahashi, Paul Y. , Mielke, Michelle M , Remaley, Alan T , Bielinski, Suzette , Larson, Nicholas B , Moser, Ethan D , Sauver, Jennifer L. St. , Olson, Janet E. , Decker, Paul A. , Bielinski, Suzette J.

Mayo Clinic

Neurology | July 5, 2023 | Volume: 101 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000207595 | PMID 37407257 Get It

HLA in isolated REM sleep behavior disorder and Lewy body dementia
Yu, Eric , Krohn, Lynne , Ruskey, Jennifer A. , Asayesh, Farnaz , Shah, Zalak , Hu, Michele T. M., Montplaisir, Jacques , Gagnon, Jean‐François , Désautels, Alex , Janes, Francesco , Bernardini, Andrea , Ibrahim, Abubaker , Heidbreder, Anna , Oertel, Wolfgang H. , Janzen, Annette , Figorilli, Michela , Puligheddu, Monica , Mollenhauer, Brit , Trenkwalder, Claudia , Sixel‐Döring, Friederike , Dijkstra, Femke, Viaene, Mineke , Abril, Beatriz, Scholz, Sonja W. , May, Patrick , Dauvilliers, Yves , Bernardini, Andrea , Stefani, Ambra , Janzen, Annette , Antelmi, Elena , Cochen De Cock, Valérie , Ferini-Strambi, Luigi , Rouleau, Guy Armand , Postuma, Ronald B , Scholz, Sonja W , Gan-Or, Ziv , May, Patrick , Ibrahim, Abubaker , Janes, Francesco , Figorilli, Michela , Puligheddu, Monica , Heidbreder, Anna , Spiegelman, Dan , Chia, Ruth , Arnulf, Isabelle , Hu, Michele T. M., Dauvilliers, Yves , Gigli, Gian Luigi , Valente, Mariarosaria , Högl, Birgit , Stefani, Ambra , Šonka, Karel , Dušek, Petr , Kemlink, David , Plazzi, Giuseppe , Antelmi, Elena , Boeve, Bradley F. , Postuma, Ronald B. , Gan‐Or, Ziv

Mayo Clinic

Annals of Clinical and Translational Neurology | July 4, 2023 | Volume: 10 | Issue: 9 | Pages: 1682-1687

10.1002/acn3.51841 | PMID 37401389 Get It

AbstractSynucleinopathies‐related disorders such as Lewy body dementia (LBD) and isolated/idiopathic REM sleep behavior disorder (iRBD) have been associated with neuroinflammation. In this study, we examined whether the human leukocyte antigen (HLA) locus plays a role in iRBD and LBD. In iRBD, HLA‐DRB1*11:01 was the only allele passing FDR correction (OR = 1.57, 95% CI = 1.27–1.93, p = 2.70e‐05). We also discovered associations between iRBD and HLA‐DRB1 70D (OR = 1.26, 95%CI = 1.12–1.41, p = 8.76e‐05), 70Q (OR = 0.81, 95%CI = 0.72–0.91, p = 3.65e‐04) and 71R (OR = 1.21, 95%CI = 1.08–1.35, p = 1.35e‐03). Position 71 (pomnibus = 0.00102) and 70 (pomnibus = 0.00125) were associated with iRBD. Our results suggest that the HLA locus may have different roles across synucleinopathies.